Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | EML4 - ALK |
| Therapy | Alectinib |
| Indication/Tumor Type | malignant peripheral nerve sheath tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK | malignant peripheral nerve sheath tumor | predicted - sensitive | Alectinib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with Alecensa (alectinib) treatment resulted in a partial response with disease control ongoing for at least 48 months in a patient with metastatic peripheral malignant nerve sheath tumor harboring EML4-ALK (PMID: 42444827). | 42444827 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (42444827) | Case Report: A case series on actionable genomic alterations guiding effective targeted therapy in rare sarcomas. | Full reference... |